GlassScriptPhysician profile
Ellis Christian
NPI 1376898122
$5,001.73
in general payments reported to CMS, 2019-2025
28 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $422 · 2021: $597 · 2022: $565 · 2023: $640 · 2024: $1,155 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,175.58 | 2019-2024 | Aveir, Diamondback Peripheral, Supera |
| Medtronic, INC. | $427.68 | 2021-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Corevalve Evolut R |
| Cardiovascular Systems INC. | $424.40 | 2019 | |
| Medtronic Vascular, INC. | $332.23 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $271.44 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $258.36 | 2021-2025 | Lifevest |
| Astellas Pharma US INC | $251.75 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $204.91 | 2019-2024 | Xarelto |
| Pfizer INC. | $188.54 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $188.32 | 2021-2025 | Camzyos, Eliquis |
| Cardiva Medical, INC. | $176.34 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Ensoetm, Cardiva Vascade 6/7f Vcs |
| Abiomed | $156.19 | 2019-2025 | Impella |
| Amgen INC. | $147.53 | 2023-2024 | Repatha |
| Biosense Webster, INC. | $124.34 | 2024 | Carto 3 |
| Shockwave Medical, INC | $108.74 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $105.41 | 2020-2025 | |
| Cvrx, INC. | $98.86 | 2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $55.45 | 2020-2022 | |
| Welch Allyn | $43.67 | 2021 | |
| Merck Sharp & Dohme LLC | $36.43 | 2023 | Verquvo |
| Boston Scientific Corporation | $35.82 | 2022-2023 | Rezum Generator |
| Atricure, INC. | $32.85 | 2022 | |
| Alnylam Pharmaceuticals INC. | $28.48 | 2023 | Onpattro |
| Sanofi-Aventis U.S. LLC | $21.22 | 2022 | |
| W. L. Gore & Associates, INC. | $15.95 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Baxter Healthcare | $14.96 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $13.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellis Christian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.